达格列净联合托拉塞米治疗慢性心力衰竭 患者的效果

打开文本图片集

[Abstract]Objective： This study aims to evaluate the efficacy and safety Dapagliflozin combined with Torasemide in the treatment patients with chronic heartfailure （CHF）.Method：A total1O6 CHF patients who were treated in from June 2O22 to June 2O24 were selected and divided into the study group ，treated with Dapagliflozin combined with Torasemide） and the control group （ n =53， treated with Torasemide）byrandom number table method，the treatment duration were8 weeks.Theclinical eficacy，left ventricular remodeling indicators [left ventricular remodeling index （LVRI）and left ventricular mass index （LVMI），left ventricular ejection fraction （LVEF）and left ventricular end-diastolic diameter（LVEDD）]，NYHAcardial function clasification，6 minute walking test （6MWT），and the incidence adverse reactions were compared between the two groups.Result： The total clinical effective rate the study group was 92.45% ，significantly higher than 77.36% the control group （P<0.05 .TheLVMIandLVEDDdecreased，LVRIandLVEFincreasedinboth groups after treatment， the study group was superior to the control group P<0.05 .TheNYHAcardiacfunction classification and 6MWT distance in the study group were better than those in the control group （ P <0.05）. There was no significant difference in the incidence adverse reactions between the two groups （ P>0.05 ）.Conclusion：Dapagliflozin combined with Torasemidecansignificantlyimprovecardiacfunctionandleftventricularremodeling inpatients with CHF，without increasing the risk adverse reactions.

[KeyWords] Chronic heart failureDapagliflozin TorasemideLeft ventricular remodeling Cardiac function Adverse reactions

First-author's addres： Department Cardiovascular Medicine， ， tuijin342500，China

doi：10.3969/j.issn.1674-4985.2025.21.004

慢性心力衰竭（CHF）是各种心血管疾病的终末阶段，其特征为心脏泵血或充盈能力受损，导致全身组织灌注不足与液体潴留]。（剩余5798字）